SAN DIEGO, Jan. 12, 2019 Johnson Fistel, LLP announces that
class actions have commenced on behalf of shareholders of the
following companies:
Sogou Inc. (NYSE: SOGO) [click here to join this
action]
Immunomedics, Inc. (NASDAQ: IMMU) [click
here to join this action]
Ternium S.A. (NYSE: TX)
[click here to join this action]
Sogou Inc. (SOGO)
Shareholder Rights Law Firm Johnson
Fistel, LLP announces that a class action lawsuit has commenced on
behalf of persons or entities who purchased or otherwise acquired
securities of Sogou Inc. (NYSE:SOGO) pursuant and/or traceable to
Sogou's November 9, 2017 Initial
Public Offering ("IPO"). The lawsuit seeks to recover damages for
Sogou investors under the federal securities laws.
According to the lawsuit, the Registration Statement and
Prospectus issued in connection with Sogou's IPO was materially
false and misleading and failed to disclose that: (1) Chinese
regulators were analyzing Sogou for regulatory action for various
reasons, including an increase in counterfeit goods sold by Sogou
merchants, and Sogou's existing software and procedures were
insufficient to safeguard against compliance violations; (2)
Sogou's cost of revenues were skyrocketing primarily due to
significant increases in Traffic Acquisition Cost, a primary driver
of Sogou's cost of revenues; (3) Sogou was going to alter its
strategy concerning smart hardware and push its artificial
intelligence ("AI") capabilities to increase product
competitiveness; (4) as a result of altering its smart hardware
strategy, Sogou decided to phase out non-AI-enabled hardware
products, such as legacy models of Teemo Smart Watch, and
transition to use products integrating AI technologies, which Sogou
hoped would reduce its hardware revenues in the second half of
2018; and (5) as a result, Sogou's public statements were
materially false and misleading at all relevant times.
Shareholders have until March 11,
2019, to seek appointment as a lead
plaintiff. There is no cost or obligation to you. Your ability to
share in any future recovery is not dependent upon serving as a
lead plaintiff.
If you are interested in learning more about your legal
rights and remedies, please contact Jim
Baker (jimb@johnsonfistel.com) at 619-814-4471. If you
email, please include your phone number.
Additionally, you can [click here to join this action]. There
is no cost or obligation to you.
Immunomedics, Inc. (IMNU)
Shareholder Rights Law Firm
Johnson Fistel, LLP announces that a class action lawsuit has
commenced on behalf of persons or entities who purchased or
otherwise acquired securities of Immunomedics, Inc. (NASDAQ:IMMU)
from August 23, 2018 through
December 20, 2018, inclusive (the
"Class Period").
According to the lawsuit, defendants throughout the Class Period
made false and misleading statements and failed to disclose that
the FDA cited Immunomedics in August
2018 for a host of violations observed at its Morris Plains, NJ facility. According to the
complaint, these violations included the manipulation of bioburden
samples, misrepresentation of an integrity test procedure in the
batch record, and the backdating of batch records.
Shareholders have until February 25, 2019, to seek
appointment as a lead plaintiff. There is no cost or obligation to
you. Your ability to share in any future recovery is not dependent
upon serving as a lead plaintiff.
If you are a long-term shareholder of
Immunomedics continuously holding shares before
August 23, 2018, you may have
standing to hold Immunomedics harmless from the alleged harm caused
by the officers and directors of the Company by making them
personally responsible. You may also be able to assist in reforming
the Company's corporate governance to prevent future
wrongdoing.
If you are interested in learning more about your legal
rights and remedies, please contact Jim
Baker (jimb@johnsonfistel.com) at 619-814-4471. If you
email, please include your phone number.
Additionally, you can [click here to join this action]. There
is no cost or obligation to you.
Ternium S.A.
Shareholder Rights Law Firm Johnson Fistel, LLP announces that a
class action lawsuit has commenced on behalf of persons or entities
who purchased or otherwise acquired securities of Ternium S.A.
(NYSE:TX) from May 1, 2014 through
November 27, 2018, inclusive (the
"Class Period").
According to the lawsuit, Defendants made false and misleading
statements and failed to disclose that: (1) Defendant Rocca,
Ternium's Chairman, knew that one of his company's executives paid
cash to government officials from 2009 to 2012 to expedite
compensation payments for the sale of Ternium's Sidor unit; (2)
this conduct would lead Rocca to be charged in a graft scheme and
subject Ternium, its affiliates, and/or its executives to
heightened governmental scrutiny; and (3) as a result, Ternium's
public statements were materially false and/or misleading at all
relevant times.
Shareholders have until January 28,
2019, to seek appointment as a lead
plaintiff. There is no cost or obligation to you. Your ability to
share in any future recovery is not dependent upon serving as a
lead plaintiff.
If you are interested in learning more about your legal
rights and remedies, please contact Jim
Baker (jimb@johnsonfistel.com) at 619-814-4471. If you
email, please include your phone number.
Additionally, you can [click here to join this action].
There is no cost or obligation to you.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York, and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
View original
content:http://www.prnewswire.com/news-releases/johnson-fistel-llp-notifies-investors-of-class-actions-against-sogou-inc-immunomedics-inc-and-ternium-sa-investors-encouraged-to-contact-firm-300777215.html
SOURCE Johnson Fistel, LLP